Introduction {#S0001}
============

COPD is a chronic inflammatory disorder with irreversible and progressive limitation of expiratory airflow, mainly affecting the small airways, that is associated with systemic inflammation and multiorgan involvement.[@CIT0001] It was estimated that COPD had caused 3.2 million deaths worldwide in 2015.[@CIT0002] In Europe, 40 million people have different stages of COPD, of which 60% suffer from significantly impaired lung function.[@CIT0003]

Different risk factors have been suggested for COPD development, including genetic and environmental factors; however, cigarette smoking is known to be the most damaging factor.[@CIT0004] Other risk factors include passive smoking, hyperreactivity of airways, occupational exposure, air pollution, male sex, advanced age, respiratory infection, and low socioeconomic status.[@CIT0002],[@CIT0005]--[@CIT0007]

There is a significant correlation between vitamin D~3~ deficiency and COPD severity. Vitamin D~3~ plays an important role in COPD pathogenesis.[@CIT0008] It has a variety of effects on human bodyfunction, including reduced cell proliferation,[@CIT0009] increased apoptosis, and[@CIT0010] enhanced differentiation. Vitamin D~3~ is also a potent regulator of such biological phenomena as angiogenesis, extracellular matrix production, and immunoresponse.[@CIT0011] Vitamin D~3~ supplementation decreases the risk of acute respiratory infections and exacerbations of asthma.[@CIT0002] Jolliffe et al showed beneficial effects of vitamin D~3~ in patients with COPD who had suffered vitamin D~3~ deficiency (\<10 ng/mL).[@CIT0002] They also confirmed that vitamin D~3~ metabolites play a key role in inducing anti-infection effector mechanisms and decrease inflammatory responses.[@CIT0002] There have been fewer studies done on the role of vitamin D~3~ in patients with COPD. Vitamin D~3~ may affect quality of life, lung function, and number of exacerbations in patients with COPD.[@CIT0006],[@CIT0007],[@CIT0012] Han et al investigated the effects of vitamin D~3~ in rat models of COPD.[@CIT0012] They showed that vitamin D~3~ was able significantly to reduce inflammation and improve lung function. They believed that vitamin D~3~ could be a novel clinical approach to treat patients with COPD.[@CIT0012]

There have not been any randomized, double blinded, placebo-controlled clinical trials done on the effectiveness of vitamin D~3~ supplementation in patients with COPD. This study was designed to evaluate the effectiveness of vitamin D~3~ on quality of life، lung function, and number of exacerbations in patients with COPD.

Methods {#S0002}
=======

A randomized, double-blinded, placebo-controlled clinical trial was conducted on patients who had been referred to the respiratory clinic of Razi Hospital between August and December 2015 ([Figure 1](#F0001){ref-type="fig"}). This was a pilot study, and the sample size was set at 30 patients in both the control and intervention groups. Levels of vitamin D~3~ were measured in eligible patients before intervention. Sampling was performed in the same season, with the same daily activity and the same sunlight exposure.Figure 1Study flowchart (CONSORT format).

Patients who were included had 10--30 ng/mL vitamin D~3~ as per GOLD guidelines.[@CIT0013] Cell counts, liver-function tests, ischemic electrocardiographic changes, calcium, phosphorus, andalkaline phosphatase of eligible patients were normal. Patients with COPD were stable in terms of physical and clinical health.

Patients not included had congestive heart failure, osteoporosis, acute myocardial infarction, glomerular filtration rate ≤45 mL/min/1.73 m2,[@CIT0014] hypercalcemia (\~\>10.3), malignancy, and sarcoidosis. In addition, patients who had used long-term azithromycin, with very low levels of vitamin D~3~ (\<10 ng/mL), and who took antiepileptic drugs were excluded.

Clinical symptoms of eligible patients included shortness of breath, especially during physical activities, wheezing, chest tightness, clearing the throat first thing in the morning, and a chronic cough with mucus (sputum).

Primary outcomes of the study were quality of life measured by COPD Assessment Test (CAT) score and lung function evaluated by spirometry of patients with COPD. It is important to say that chest X-rays were not used for patients with COPD.

Study valuables comprised age, sex, body-mass index, cigarette smoking, FEV~1~, FEV~1~/FVC, number of exacerbations, CAT score, COPD severity, and vitamin D~3~ in blood.

Patients with COPD received 0.5--1 mg steroid per kilogram of body weight when exacerbating for 7--14 days. Both patients and questioners did not have any information from the study groups. Subsequently, placebo (gelatin) and vitamin D~3~ were placed in two separate envelopes, then classified according to random blocks. We used stored plasma samples to measure circulating vitamin D~3~metabolites, which is the accepted biomarker for vitamin D~3~.[@CIT0015] In the next stage, radioimmunoassays wereconducted to measure vitamin D~3~ levels.[@CIT0016]

Finally, 63 patients remained: 32 for intervention and 31 as controls. The study received ethics approval from the Committee on Publication Ethics of Guilan University of Medical Sciences, and patients filed written informed consent. General health questionnaires were used to enroll patients with symptoms of COPD. The CAT questionnairewas first translated into Persian and then back into English.

Patients placed in the intervention group took 50,000 IU vitamin D~3~, and those in the control group received placebo once a week for 8 weeks, then once a month for 4 months. After 6 months, the same questionnaire was used. Double-blinding was applied on both patients and care providers during the study.

Statistical analysis {#S0003}
====================

The *χ*^2^ test was performed to compare qualitative variables between two groups. Normal parameter distribution was checked by Kolmogorov--Smirnov test. Student\'s *t*-test and paired *t*-test were used for variables distributed normally. Mann--Whitney *U* and Wilcoxon tests were performed on variables that did not have normal distribution. Two-tailed *P*\<0.05 was considered significant.

Results {#S0004}
=======

In this study, 30 men (93.8%) and two women (6.3%) were in the intervention group and 30 men (96.8%) and a woman (3.2%) in the placebo group. The mean age of those in the intervention group was 67.9±7.9 years and in the placebo 68.4±7.8 years.

At the beginning of the study, FEV~1~, FEV~1~/FVC, and CAT scores, number of exacerbations, and percentage of severity did not show significant differences between the intervention and control groups (*P*\>0.05, [Table 1](#T0001){ref-type="table"}). Neither FEV1 nor FEV1/FVC showed significant differences between the intervention and control groups ([Table 2](#T0002){ref-type="table"}). There were significant differences in serum levels of vitamin D~3~ between the intervention and control groups (51.83 vs 19.43 ng/mL) within 2--6 months from baseline (*P*\<0.001, [Table 2](#T0002){ref-type="table"}). There were no statistical differences in exacerbations between the groups after 2 months, within 2--6 months, or after 6 months from baseline. In addition, the qualitative analysis showed that exacerbations had not worsened after 6 months in the intervention group ([Table 3](#T0003){ref-type="table"}). CAT scores showed statistical differences between the groups at 2 months from baseline in quality of life at every stage in the intervention group ([Table 3](#T0003){ref-type="table"}).Table 1Studied variables before intervention in both control and vitamin D groupsVariablesGroup*P*-valueIntervention (vitamin D~3~)Control (placebo)The beginning of the studyAge (years)67.9±7.968.4±7.80.748\*Sex (male)30 (93.8%)30 (96.8%)0.573\*\*BMI (kg/m^2^)24.33±2.1324.55±1.940.665\*Cigarette smoking (per year) (mean ± SD)32±1431±130.866\*FEV~1~ (mean ± SD)57.98±17.6757.7±17.990.949\*FEV~1~/FVC (mean ± SD)56.75±1258.76±9.820.472\*Exacerbations, n (~~%~~)10 (31.3%)11 (35.5%)0.722\*\*\*Exacerbations (mean ± SD)0.53±0.980.55±0.850.658\*\*\*\*CAT score (mean ± SD)15.3±7.3515.48±9.320.767\*\*\*\*COPD severity, n (%)6 (18.8%)9 (29%)0.294\*\*16 (50%)9 (29%)5 (15.6%)9 (29%)5 (15.6%)4 (12.9%)25-Hydroxyvitamin D~3~ levels, ng/mL, (mean ± SD)19.33±5.1818.55±4.580.528\*[^1][^2] Table 2Studied variables at 2 and 6 months after intervention in both control and vitamin D groupsIntervention (vitamin D~3~)Control (placebo)*P*-valueAfter 2 monthsFEV~1~ (mean ± SD)58.69±17.6857.87±18.060.857\*FEV~1~/FVC (mean ± SD)57.43±12.0958.9±9.560.593\*Exacerbations, n (%)3 (9.4%)3 (9.7%)\>0.999\*\*Exacerbations (mean ± SD)0.09±0.30.1±0.30.968\*\*\*\*CAT score14.25±7.4315.29±9.530.842\*\*\*\*COPD severity, n (% )A6 (18.8%)6 (19.4%)0.665\*\*B15 (46.9%)14 (45.2%)C3 (9.4%)6 (19.4%)D8 (25%)5 (16.1%)After 6 monthsFEV~1~ (mean ± SD)58.93±17.7358.18±17.910.868\*FEV~1~/FVC (mean ± SD)57.74±11.8659.2±9.990.6\*Exacerbations, n (%)4 (12.5%)8 (25.8%)0.179\*\*\*Exacerbations (mean ± SD)0.16±0.450.32±0.60.184\*\*\*\*CAT score (mean ± SD)13±7.4715.65±9.460.250\*\*\*\*COPD severityA6 (18.8%)6 (19.4%)0.979\*\*\*B14 (43.8%)13 (41.9%)C5 (15.6%)6 (19.4%)D7 (21.9%)6 (19.4%)25-hydroxyvitaminD~3~ levels (mean ± SD),\
ng/mL51.83±7.9319.43±5.22\<0.001\*[^3][^4] Table 3Mean differences in studied variables in both control and vitamin D groupsVariablesDurationGroupMean ± SD*P*-valueFEV~1~After 2 months from baselineIntervention0.7±1.110.073\*Control0.18±1.19Between 2 and 6 months from baselineIntervention0.25±0.740.820\*Control0.31±1.44After 6 months from baselineIntervention0.95±1.880.089\*Control0.49±1.22FEV~1~/FVCAfter 2 months from baselineIntervention0.67±1.270.116\*Control0.15±1.35Between 2 and 6 months from baselineIntervention0.32±1.030.944\*Control0.3±1.17After 6 months from baselineIntervention0.99±1.280.640\*\*Control0.45±1.51ExacerbationsAfter 2months from baselineIntervention−0.44±1.010.431\*\*Control−0.45±0.77Between 2 and 6 months from baselineIntervention0.06±0.50.129\*\*Control0.23±0.5After 6 months from baselineIntervention−0.38±0.830.613\*\*Control−0.23±0.72CAT scoreAfter 2 months from baselineIntervention−1.09±1.030.001\*\*Control0.19±1.01Between 2 and 6 months from baselineIntervention−1.25±1.63\<0.001\*\*Control0.35±1.02After 6 months from baselineIntervention−2.34±1.41\<0.001\*\*Control0.16±1.04[^5][^6]

Discussion {#S0005}
==========

The current study reported a randomized, double-blinded, placebo-controlled clinical trial on the effect of vitamin D~3~ supplementation on lung function and quality of life in patients with COPD. Janssens et alshow that serum levels of vitamin D~3~ had significant correlations with the severity of COPDand exacerbations.[@CIT0017] They also observed that vitamin D~3~ consumption improved pulmonary function and quality of life in COPD patients in six months. Patients were controlled with different doses of vitamin D~3~. Serum vitamin D~3~ in the intervention group increased from 19.33 to 51.83 ng/mL. Subsequently, quality of life and pulmonary function began to recover and exacerbations in patients with COPD were reduced. Furthermore, Lehouck et alreported that vitamin D~3~ may reduce acute exacerbations of COPD symptoms in those with initially deficient levels.[@CIT0018] On the other hand, Hornikx et al showed prescribing 3 mg vitamin D~3~ every 2 months over 1 year also maintain moderate or acute exacerbations, but not for upper respiratory tract infections (\<50 nmol/L or 20 ngr/mL).[@CIT0019] They demonstrated that consuming 100.000 IU vitamin D~3~ 3 months significantly improved inspiratory muscle strength and maximal oxygen uptake.[@CIT0019] In other words, deficient vitamin D~3~ can also reduce actin and troponin, impair calcium uptake in the sarcoplasmic reticulum, adjust protein synthesis, and increase apoptosis[@CIT0020] Banerjee et al demonstrated that vitamin D~3~ stimulated the airway smooth-muscle cells to express vitamin D~3~ receptors and regulated inflammation, contraction, and remodeling in other cell types.[@CIT0021]

Other studies found higher levels of vitamin D~3~--binding protein in patients with COPD, which involved neutrophil chemotaxis and macrophage activation (which has an important role in COPD pathogenesis). Vitamin D~3~-binding protein has a significant correlation with serum levels of vitamin D; therefore, increasing vitamin D~3~ levels will increase those of vitamin D~3~--binding protein.[@CIT0022],[@CIT0023]

However, Jolliffe et al found no effect of vitamin D~3~ supplementation on the rate of exacerbations among patients with COPD, but that vitamin D~3~ supplementation has protective effects on patients with low vitamin D~3~ (\<25 nmol/L).[@CIT0002]

The findings of this study have some limitations. Firstly, this study was single-centered; therefore, the results require further investigation. Secondly, liver function, electrocardiography, calcium, and albumin of COPD patients were not measured. Thirdly, the sample was small and there was low power to detect an effect from vitamin D~3~. There has not been a study done on lung function, number of exacerbations, and quality of life in patients with COPD. Further studies seem to be required in this field.

As believed, consumption of vitamin D~3~ improves quality of life in COPD patients.

According to the evidence, getting 10,000 IU/day in patients with deficienct levels of vitamin D~3~ (1,500--2,000 IU/day) would not be toxic.[@CIT0022] Undoubtedly, vitamin D~3~ therapy cheap, which and could be one of its important advantages.[@CIT0023] Finally, vitamin D~3~ therapy could be a useful and safe optionsimultaneously with other procedures.

Conclusion {#S0006}
==========

Vitamin D~3~ (50,000 IU) supplementation can improve quality of life in patients with COPD. In fact, COPD might be controlled by different levels of vitamin D~3~ in serum. We found that consuming 50,000 IU vitamin D~3~ increased quality of life in COPD. In addition, we found that exacerbations had not worsened after 6 months.
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[^1]: **Notes:** \*t-test; \*\*Fisher's exact test, \*\*\*Chi squre; \*\*\*\*Mann--whitney.

[^2]: **Abbreviations:** BMI, body mass index; CAT score, COPD assessment test score; FEV1, Forced expiratory volume at first second; FVC, Forced vital capacity.

[^3]: **Notes:** \*Student\'s t-test; \*\*Fisher's exact test; \*\*\*χ2; \*\*\*\*Mann--Whitney U test.

[^4]: **Abbreviation:** CAT, COPD Assessment Test.

[^5]: **Notes:** \*Student\'s *t*-test; \*\*Mann--Whitney *U* test.

[^6]: **Abbreviation:** CAT, COPD Assessment Test.
